{"generic":"Sodium Tetradecyl Sulfate","drugs":["Sodium Tetradecyl Sulfate","Sotradecol"],"mono":{"0":{"id":"556965-s-0","title":"Generic Names","mono":"Sodium Tetradecyl Sulfate"},"1":{"id":"556965-s-1","title":"Dosing and Indications","sub":{"0":{"id":"556965-s-1-4","title":"Adult Dosing","mono":"<b>Venous varices:<\/b> 0.5 to 2 mL (preferably 1 mL) IV into the vein intended for sclerosis; the 1% solution is used most often, with the 3% solution being reserved for larger varicosities; MAX single treatment, do not exceed 10 mL "},"3":{"id":"556965-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Venous varices<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Esophageal varices<\/li><li>Hemangioma<\/li><\/ul>"}}},"3":{"id":"556965-s-3","title":"Contraindications\/Warnings","sub":[{"id":"556965-s-3-9","title":"Contraindications","mono":"<ul><li>Acute cellulitis<\/li><li>Acute infections<\/li><li>Acute superficial thrombophlebitis<\/li><li>Allergic conditions<\/li><li>Bedridden patients<\/li><li>Huge superficial veins with wide open communications to deeper veins<\/li><li>Phlebitis migrans<\/li><li>Previous hypersensitivity reactions to the drug<\/li><li>Significant valvular or deep vein incompetence<\/li><li>Uncontrolled systemic diseases (diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias and acute respiratory or skin diseases)<\/li><li>Varicosities caused by abdominal and pelvic tumors unless the tumor has been removed<\/li><\/ul>"},{"id":"556965-s-3-10","title":"Precautions","mono":"<ul><li>Allergic reactions, including fatal anaphylaxis have been reported<\/li><li>Do not administer sclerotherapy if tests, such as the Trendelenburg and Perthes, and angiography show significant valvular or deep venous incompetence<\/li><li>Extravasation<\/li><li>Patients with underlying arterial diseases, such as peripheral arteriosclerosis or thromboangiitis obliterans (Buerger's disease)<\/li><\/ul>"},{"id":"556965-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"556965-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"556965-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site ulcer, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Nausea, Vomiting<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, eg, asthma, hives, hayfever<\/li><li><b>Neurologic:<\/b>Headache, Pain<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Deep venous thrombosis<\/li><li><b>Dermatologic:<\/b>Necrosis, following extravasation, Skin necrosis, following extravasation<\/li><li><b>Immunologic:<\/b>Anaphylaxis, death reported<\/li><li><b>Respiratory:<\/b>Pulmonary embolism<\/li><\/ul>"},"6":{"id":"556965-s-6","title":"Drug Name Info","sub":{"0":{"id":"556965-s-6-17","title":"US Trade Names","mono":"Sotradecol<br\/>"},"2":{"id":"556965-s-6-19","title":"Class","mono":"Sclerosing Agent<br\/>"},"3":{"id":"556965-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"556965-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"556965-s-7","title":"Mechanism Of Action","mono":"Sodium tetradecyl sulfate, an anionic surfactant, is a sclerosing agent that produces inflammation of the intima and formation of a thrombus, which results in vein occlusion in the treatment of varicose veins. Subsequent fibrous tissue formation may lead in partial or complete vein obliteration.<br\/>"},"9":{"id":"556965-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/>for IV use only <br\/>"},"10":{"id":"556965-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>signs and symptoms of thrombosis<\/li><li>signs and symptoms of extravasation<\/li><\/ul>"},"11":{"id":"556965-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>  Solution: 27 %<br\/><\/li><li><b>Sotradecol<\/b><br\/>Intravenous Solution: 1 %, 3 %<br\/><\/li><\/ul>"},"13":{"id":"556965-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause injection site ulcer, nausea, vomiting, headache, or pain.<\/li><li>Advise patient to report signs\/symptoms of deep venous thrombosis, skin necrosis, or pulmonary embolism.<\/li><li>Patient should monitor for and report extravasation during drug administration.<\/li><\/ul>"}}}